Join Growin Stock Community!

Genenta science s.p.a.GNTA.US Overview

US StockHealthcare
(No presentation for GNTA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

GNTA AI Insights

GNTA Overall Performance

GNTA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

GNTA Recent Performance

-4.11%

Genenta science s.p.a.

0.05%

Avg of Sector

-0.31%

S&P500

GNTA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

GNTA Key Information

GNTA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

GNTA Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.

Price of GNTA

GNTA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

GNTA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.45
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.63
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.45
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.63
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is GNTA's latest earnings report released?

    The most recent financial report for Genenta science s.p.a. (GNTA) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GNTA's short-term business performance and financial health. For the latest updates on GNTA's earnings releases, visit this page regularly.

  • How much cash does GNTA have?

    At the end of the period, Genenta science s.p.a. (GNTA) held Total Cash and Cash Equivalents of 5.18M, accounting for 0.24 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is GNTA's EPS continuing to grow?

    According to the past four quarterly reports, Genenta science s.p.a. (GNTA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.2. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of GNTA?

    Genenta science s.p.a. (GNTA)'s Free Cash Flow (FCF) for the period is -5.52K, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 168.06% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.